New SIMPONI (Golimumab) Data Shows Sustained Efficacy in the Treatment of Rheumatoid Arthritis
- Details
- Category: Merck
Findings from an open-label, uncontrolled long-term extension of a Phase 3 registration trial demonstrated efficacy of SIMPONI in patients with moderately to severely active rheumatoid arthritis despite methotrexate therapy at two years.
FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients
- Details
- Category: Novartis
Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that RoACTEMRA (known as ACTEMRA outside Europe) is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, and OncoMed Pharmaceuticals, Inc., announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.
Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix
- Details
- Category: Abbott
Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis.
Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients
- Details
- Category: Boehringer Ingelheim
Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years.
Genzyme's Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).
More Pharma News ...
- Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL
- Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint
- FDA advisory committee recommends approval of Novartis investigational treatment FTY720
- GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix
- AVERROES Study Closes Early Due to Clear Evidence of Efficacy
- Ranbaxy Launches Antiplatelet Agent Prasugrel in India
- Americans Are Not Taking Action to Protect Themselves Against Muscle Loss